[Moxibustion Plus Medication Can Relieve Refractory Nausea and Vomiting and Improve Quality of Life of Advanced Cancer Patients Undergoing Chemical Therapy].

The requested reference [c5c0e30152fcbf19fd255d59b76951e9c509f5f7] no longer exists in our database. It has been replaced by the current reference: [d113f34e5185113433e6b90c3841312609506add]

Authors
Category Primary study
JournalZhen ci yan jiu = Acupuncture research
Year 2018
OBJECTIVE: To explore the efficacy of moxibustion combined with medication in the treatment of refractory nausea and vomiting and quality of life (QOL) in advanced cancer patients. METHODS: A total of 266 advanced cancer patients with nausea and vomiting were randomly assigned to Metoclopramide group (M group, n=70), Metoclopramide plus Haloperidol group (MH group, n=65), moxibustion + M group (n=63), and moxibustion + MH group (n=68). Moxibustion was applied to bilateral Zusanli (ST 36), and Guanyuan (CV 4), Qihai (CV 6) for 20 min every time, twice a day for 2 weeks. The Rhodes' Index of nausea, Vomiting and Retching (INVR) was used for assessing the state of these symptoms in duration, frequency and severity (40 points), the 24-item Hamilton Depression Rating Scale (HAMD, 0-76 points) was employed to measure the patients' depression severity, and the Functional Assessment of Cancer Therapy-General (FACT-G, including physical, social/family, emotional, and functional dimensions, 27 items, 108 points) was adopted to measure the cancer patients' QOL. RESULTS: Following the treatment, the INVR and HAMD scores were significantly decreased in the M, MH, moxibusion+M and moxibustion+MH groups in comparison with their own pretreatment (P<0.05) and were significantly lower in the moxibustion+MH group than in the M, MH and moxibustion+M groups (P<0.05). The FACT-G scoring outcomes showed that the scores of physical well-being, emotional well-being, and total score of QOL were significantly higher in the MH, moxibustion+M and moxibustion+MH groups than in the M group, and were significantly higher in the moxibustion+MH group than in the MH and moxibustion+M groups (P<0.05). No significant differences were found between the MH and moxibustion+M groups in the INVR and HAMD scores, and in the scores of physical well-being, emotional well-being and total score of QOL (P>0.05).. CONCLUSION: Moxibustion plus Metoclopramide and Haloperidol can relieve refractory nausea and vomiting, and better depression and QOL in advanced cancer patients, being worthy of popularization in clinical practice.
Epistemonikos ID: b37366a5f6a5e73a19538b85034128d41ef614de
First added on: May 07, 2022